Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103506 · ClinicalTrials.gov registry record · Phase 3
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
- 20
- Study locations
NCT00103506 is a Phase 3 study of Multiple Myeloma that has completed, run by Janssen Research & Development. The registered enrollment target is 646 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00103506, a Phase 3 study of Multiple Myeloma, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
Conditions Studied
Interventions
- DRUG Bortezomib (VELCADE)
- DRUG Doxorubicin hydrochloride (DOXIL/CAELYX)
Study Locations (20)
California
- - Berkeley
- - Loma Linda
- - Los Angeles
- - Sacramento
Florida
- - Jacksonville
- - Miami
- - Stuart
- - West Palm Beach
Connecticut
- - Norwalk
- - Stamford
Louisiana
- - Metairie
- - New Orleans
Alabama
- - Alabaster
Arizona
- - Surprise
Georgia
- - Altanta
Idaho
- - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2004-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103506
The ClinicalTrials.gov registry entry for NCT00103506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (19% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib (VELCADE) is the first listed.
NCT00103506 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00103506 about?
NCT00103506 is a clinical study titled "Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma". The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
What is the current status of trial NCT00103506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2004-12. Estimated completion is 2014-06.
What conditions does trial NCT00103506 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00103506?
The interventions under investigation include: Bortezomib (VELCADE) (DRUG), Doxorubicin hydrochloride (DOXIL/CAELYX) (DRUG).
Who is sponsoring clinical trial NCT00103506?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103506 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.